Amiodarone Pulmonary Toxicity: A Patient with Three Recurrences of Pulmonary Toxicity and Consideration of the Probable Risk for Relapse

Kaori Okayasu, Yuichiro Takeda, Jun Kojima, Atsuto Yoshizawa, Nobuyuki Kobayashi, Haruhito Sugiyama, Koichiro Kudo

Internal Medicine · 2006 · 36 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

A 44-year-old man was treated with amiodarone for dilated cardiomyopathy. After 53 months, he developed amiodarone-induced interstitial pneumonia. Amiodarone treatment was terminated, and the patient was given corticosteroids. These treatments were effective. However, pneumonitis recurred whenever prednisolone was reduced to less than 5 mg per day. Considering the patient's background characteristics, we considered his body mass index (BMI, kg/m(2)) and found his to be high. When four additional patients with amiodarone pulmonary toxicity were reviewed at our institute, a correlation between BMI and the duration of shadow disappearance was found (R(2)=0.8695). Because amiodarone is lipophilic, the patient's high BMI might have influenced the repeated appearance of pulmonary toxicity.

References

14